Back to top
more

Ayala Pharmaceuticals, Inc. (ADXS)

(Delayed Data from OTC)

$0.11 USD

0.11
171

+0.08 (287.82%)

Updated Nov 8, 2024 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for ADXS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Ayala Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 5 3 25 42 25
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 0 1 2 3
Total Current Assets 8 3 26 43 28
Net Property & Equipment 1 1 0 0 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 8 0 0 3 3
Deposits & Other Assets 0 2 0 0 0
Total Assets 17 8 26 47 39
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 6 4 0 0 0
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 6 2 2 3 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 1 0 5 0
Total Current Liabilities 25 8 2 8 3
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 8 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 0 0 0 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 41 9 2 8 8
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 173 148 467 467 441
Retained Earnings -197 -149 -443 -429 -411
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -24 -1 24 39 30
Total Liabilities & Shareholder's Equity 17 8 26 47 39
Total Common Equity -24 -1 24 39 30
Shares Outstanding 11.80 1.80 1.80 1.40 0.70
Book Value Per Share -2.07 -0.61 13.13 27.78 43.11

Fiscal Year End for Ayala Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 5 2
Receivables NA NA NA 0 0
Notes Receivable NA NA NA 0 0
Inventories NA NA NA 0 0
Other Current Assets NA NA NA 3 2
Total Current Assets NA NA NA 8 5
Net Property & Equipment NA NA NA 1 1
Investments & Advances NA NA NA 0 0
Other Non-Current Assets NA NA NA 0 0
Deferred Charges NA NA NA 0 0
Intangibles NA NA NA 8 0
Deposits & Other Assets NA NA NA 0 0
Total Assets NA NA NA 17 7
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA NA NA 0 0
Accounts Payable NA NA NA 6 5
Current Portion Long-Term Debt NA NA NA 0 0
Current Portion Capital Leases NA NA NA 0 0
Accrued Expenses NA NA NA 6 3
Income Taxes Payable NA NA NA 0 0
Other Current Liabilities NA NA NA 12 0
Total Current Liabilities NA NA NA 25 9
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA NA NA 0 0
Convertible Debt NA NA NA 8 2
Long-Term Debt NA NA NA 0 0
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA NA 8 2
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA NA NA 41 13
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA NA NA 0 0
Capital Surplus NA NA NA 173 166
Retained Earnings NA NA NA -197 -173
Other Equity NA NA NA 0 0
Treasury Stock NA NA NA 0 0
Total Shareholder's Equity NA NA NA -24 -6
Total Liabilities & Shareholder's Equity NA NA NA 17 7
Total Common Equity 0 0 0 -24 -6
Shares Outstanding 42.60 42.60 42.60 11.80 4.70
Book Value Per Share 0.00 0.00 0.00 -2.07 -1.33